New Drug BHB810 for Advanced Stomach Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug called BHB810 for gastric (stomach) and gastroesophageal junction cancer that has stopped responding to standard treatments or has no standard options available. The drug targets a protein called CDH17 found on cancer cells and may help slow or shrink the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- Your cancer must be confirmed by biopsy as stomach or gastroesophageal junction adenocarcinoma (a type of cancer) that is advanced and has not responded to or progressed despite prior treatments
- Your tumor must be positive for a marker called CDH17 (determined by central lab testing)
- You must have at least one measurable tumor on imaging that can be tracked during the study
- You must provide archived tumor tissue samples and may need a fresh biopsy at screening
- Your organ and bone marrow function must be adequate (blood counts and kidney/liver tests must be acceptable)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy for people with advanced stomach or gastroesophageal junction cancer that has not responded to at least two prior treatments. The therapy targets a specific protein (CLDN18.2) found on cancer cells. The goal is to see if this approach can help control the disease.
This trial tests a combination of an immunotherapy drug (PD1/TGFβ), another targeted drug (SHR2554 or apatinib), and chemotherapy for people who have not yet been treated for advanced stomach cancer. The goal is to see if this combination works better than standard treatments.
This trial tests a new study drug (SAR445877) for adults with advanced stomach or gastroesophageal junction cancer that has worsened after at least one prior treatment. It aims to find the best dose and see if the drug can help shrink or slow the cancer.
This study tests a combination of three treatments—JS107, toripalimab (an immunotherapy), and chemotherapy—for advanced stomach cancer that has a specific protein marker called CLDN18.2. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a personalized treatment approach for advanced gastric cancer. It uses unique markers in your tumor (HER2, CLDN18.2, PD-L1) to match you with targeted therapies, aiming for better results than standard chemotherapy.
This trial tests a new drug, HCB101, combined with other treatments for advanced stomach or gastroesophageal cancer. It may be an option if your tumor has a specific marker called CLDN18.2 and you haven't had prior systemic therapy.
Hear when a new Gastric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.